DK1618889T3 - Influenzavaccine - Google Patents

Influenzavaccine

Info

Publication number
DK1618889T3
DK1618889T3 DK05077465.2T DK05077465T DK1618889T3 DK 1618889 T3 DK1618889 T3 DK 1618889T3 DK 05077465 T DK05077465 T DK 05077465T DK 1618889 T3 DK1618889 T3 DK 1618889T3
Authority
DK
Denmark
Prior art keywords
antigen
influenza vaccine
vaccine
dose
combination
Prior art date
Application number
DK05077465.2T
Other languages
Danish (da)
English (en)
Inventor
Hondt Erik D
Norbert Hehme
Original Assignee
Glaxosmithkline Biolog Sa
Glaxosmithkline Biolog Niederlassung Der Smithkline Beecham Pharma Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10861908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1618889(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa, Glaxosmithkline Biolog Niederlassung Der Smithkline Beecham Pharma Gmbh & Co Kg filed Critical Glaxosmithkline Biolog Sa
Application granted granted Critical
Publication of DK1618889T3 publication Critical patent/DK1618889T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK05077465.2T 1999-09-30 2000-09-27 Influenzavaccine DK1618889T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9923176.3A GB9923176D0 (en) 1999-09-30 1999-09-30 Novel composition
EP00966084A EP1216053B1 (en) 1999-09-30 2000-09-27 Influenza vaccine

Publications (1)

Publication Number Publication Date
DK1618889T3 true DK1618889T3 (da) 2011-06-06

Family

ID=10861908

Family Applications (2)

Application Number Title Priority Date Filing Date
DK05077465.2T DK1618889T3 (da) 1999-09-30 2000-09-27 Influenzavaccine
DK00966084T DK1216053T3 (da) 1999-09-30 2000-09-27 Influenzavaccine

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK00966084T DK1216053T3 (da) 1999-09-30 2000-09-27 Influenzavaccine

Country Status (15)

Country Link
US (2) US7238349B1 (https=)
EP (4) EP2269637A1 (https=)
JP (4) JP2003510291A (https=)
AT (2) ATE309821T1 (https=)
AU (1) AU774921B2 (https=)
BR (1) BR0014386A (https=)
CA (2) CA2386014C (https=)
CY (2) CY1111908T1 (https=)
DE (3) DE122011100035I1 (https=)
DK (2) DK1618889T3 (https=)
ES (2) ES2359982T3 (https=)
GB (1) GB9923176D0 (https=)
HK (1) HK1048434B (https=)
PT (1) PT1618889E (https=)
WO (1) WO2001022992A2 (https=)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
DK1499348T3 (en) 2002-04-26 2015-01-05 Medimmune Llc PROCEDURE FOR PREPARING INFECTIOUS INFLUENZA B-VIRA IN CELL CULTURE
CA2514667C (en) * 2003-01-30 2013-01-08 Chiron Corporation Adjuvanted influenza vaccine
US20060110406A1 (en) 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
EP2481819A1 (en) * 2003-02-25 2012-08-01 MedImmune Vaccines, Inc. Cross flow filtration in the production of stabilized influenza vaccine compositions
AU2012201973B2 (en) * 2003-02-25 2014-05-22 Medimmune, Llc Methods of producing influenza vaccine compositions
TWI350174B (en) * 2003-03-12 2011-10-11 Wyeth Corp Adjuvanted bovine vaccines
CA2551489C (en) 2003-12-23 2013-09-03 Gregory Duke Multi plasmid system for the production of influenza virus
JP5600375B2 (ja) 2004-03-09 2014-10-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド インフルエンザウイルスワクチン
ATE489965T1 (de) 2004-09-09 2010-12-15 Novartis Vaccines & Diagnostic Verminderung von potentiellen iatrogenen risiken in verbindung mit influenza impfstoffen
US20090004222A1 (en) 2004-11-03 2009-01-01 O'hagan Derek Influenza Vaccination
US20090028903A1 (en) * 2005-03-23 2009-01-29 Glaxosmithkline Biologicals, S.A. Novel use
AR054020A1 (es) * 2005-03-23 2007-05-30 Glaxosmithkline Biolog Sa Nuevo uso
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
JP2009514844A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル スプリットインフルエンザワクチン用のアジュバントとしての遊離水相界面活性剤を含むエマルション
AU2006310338A1 (en) * 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Adminstration routes for priming/boosting with influenza vaccines
CA2628152C (en) 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
JP5005700B2 (ja) * 2005-11-04 2012-08-22 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル アルミニウムアジュバントに即座に吸着されるインフルエンザワクチン
NZ568212A (en) 2005-11-04 2012-03-30 Novartis Vaccines & Diagnostic Changing Th1/Th2 balance in split influenza vaccines with adjuvants
NZ594482A (en) 2005-11-04 2012-11-30 Novartis Vaccines & Diagnostic Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
NZ568211A (en) 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
CN102755645A (zh) 2005-11-04 2012-10-31 诺华疫苗和诊断有限公司 佐剂配制的包含细胞因子诱导剂的流感疫苗
PL2478916T3 (pl) 2006-01-27 2020-11-16 Seqirus UK Limited Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
US9072701B2 (en) * 2006-04-21 2015-07-07 St. Jude Children's Research Hospital Avian influenza viruses, vaccines, compositions, formulations, and methods
PT2054431E (pt) 2006-06-09 2011-11-03 Novartis Ag Confórmeros de adesinas bacterianas
WO2007144772A2 (en) * 2006-06-15 2007-12-21 Novartis Ag Adjuvant-sparing multi-dose influenza vaccination regimen
US20080014217A1 (en) * 2006-07-17 2008-01-17 Emmanuel Jules Hanon Influenza vaccine
PT2422810E (pt) * 2006-07-17 2014-12-03 Glaxosmithkline Biolog Sa Vacina da gripe
CA2583555C (en) * 2006-07-17 2020-01-07 Glaxosmithkline Biologicals S.A. Influenza vaccine
MX2009000660A (es) * 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
GB0614460D0 (en) * 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP4585610A3 (en) 2006-09-11 2025-09-24 Seqirus UK Limited Making influenza virus vaccines without using eggs
EA015817B1 (ru) 2006-10-12 2011-12-30 Глаксосмитклайн Байолоджикалс С.А. Иммуногенная композиция, содержащая адъювант в виде эмульсии "масло в воде"
GB0622282D0 (en) 2006-11-08 2006-12-20 Novartis Ag Quality control methods
PT2121011E (pt) 2006-12-06 2014-07-31 Novartis Ag Vacinas compreendendo um antigénio a partir de quatro estirpes do vírus da gripe
PE20090146A1 (es) 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
CN101085348B (zh) * 2007-06-18 2010-08-18 南京农业大学 用于禽流感灭活抗原的鼻腔免疫复合佐剂
EP2674486A1 (en) 2007-06-18 2013-12-18 MedImmune, LLC Influenza B viruses having alterations in the hemaglutinin polypeptide
KR20100045437A (ko) 2007-06-27 2010-05-03 노파르티스 아게 첨가물이 적은 인플루엔자 백신
US20090098143A1 (en) * 2007-06-29 2009-04-16 Avianax, Inc. Vaccine production for pathogenic bird viral diseases
WO2009014919A2 (en) * 2007-07-13 2009-01-29 Iowa State University Research Foundation, Inc. H2n3 influenza a viruses and methods of use
CN106310293A (zh) 2007-09-27 2017-01-11 免疫疫苗技术有限公司 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
GB0810305D0 (en) * 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
JP2011506290A (ja) 2007-12-06 2011-03-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム インフルエンザ組成物
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
AU2008339631B2 (en) 2007-12-24 2014-07-24 Novartis Ag Assays for adsorbed influenza vaccines
US20120034266A1 (en) * 2008-03-04 2012-02-09 Nel Andre E Methods and compositions for improving immune response by a nutraceutical antioxidant
CN101959527B (zh) 2008-03-05 2016-04-20 赛诺菲巴斯德有限公司 一种使含佐剂的疫苗组合物稳定的方法
JP5518041B2 (ja) * 2008-03-18 2014-06-11 ノバルティス アーゲー インフルエンザウイルスワクチン抗原の調製における改良
EP2278997B1 (en) * 2008-04-21 2016-08-10 Nanobio Corporation Nanoemulsion influenza vaccine
WO2009146523A1 (en) * 2008-06-05 2009-12-10 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
EP2310045A1 (en) 2008-06-25 2011-04-20 Novartis AG Rapid responses to delayed booster immunisations
US20110150926A1 (en) 2008-08-01 2011-06-23 Mohammed Alsharifi Influenza vaccines
RU2400536C1 (ru) * 2009-01-11 2010-09-27 Федеральное государственное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФГУП ГНЦ ВБ "Вектор" Роспотребнадзора) ШТАММ ВИРУСА ГРИППА ПТИЦ A/common gull/Chany/2006 H5N1 СУБТИПА ДЛЯ ПРИГОТОВЛЕНИЯ АНТИГЕНСОДЕРЖАЩЕГО ДИАГНОСТИЧЕСКОГО ИЛИ ВАКЦИННОГО ПРЕПАРАТА
EP3173097A3 (en) 2009-02-10 2017-07-12 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
EP2411048B1 (en) 2009-03-24 2020-05-06 GlaxoSmithKline Biologicals SA Adjuvanting meningococcal factor h binding protein
USH2283H1 (en) 2009-04-27 2013-09-03 Novartis Ag Vaccines for protecting against influenza
NZ596671A (en) 2009-05-29 2013-06-28 Novartis Ag Assays for influenza virus hemagglutinins
US20120237536A1 (en) 2009-09-10 2012-09-20 Novartis Combination vaccines against respiratory tract diseases
JP5774010B2 (ja) * 2009-09-25 2015-09-02 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム インフルエンザウイルスのための免疫拡散アッセイ
MX2012004067A (es) 2009-10-09 2012-08-03 Cbio Ltd Variantes de la chaperonina 10.
RS52565B (sr) 2009-12-03 2013-04-30 Novartis Ag Metod interakcije i komore sa povratnim pritiskom za mikrofluidizaciju
DE102009056871A1 (de) 2009-12-03 2011-06-22 Novartis AG, 4056 Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
CL2012001399A1 (es) 2009-12-03 2013-03-08 Novartis Ag Metodo para fabricar adyuvante para vacuna (emulsion aceite/agua con escualeno, polisorbato 80 y trioleato de sorbitan), que comprende (i) formar primera emulsion en homogenizador desde un contendor a otro para formar segunda emulsion, (ii) y microfluidizar primera emulsion para formar segunda emulsion.
CN104688687A (zh) 2009-12-03 2015-06-10 诺华股份有限公司 疫苗佐剂制备中的亲水过滤
DE102009056884B4 (de) 2009-12-03 2021-03-18 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
DE102009056883B4 (de) 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
EP2506834B1 (en) 2009-12-03 2016-03-02 Novartis AG Circulation of components during homogenization and microfluidization of emulsions
NZ603918A (en) 2010-05-12 2015-04-24 Novartis Ag Improved methods for preparing squalene
AU2011300402B2 (en) 2010-09-07 2015-01-22 Novartis Ag Generic assays for detection of mammalian reovirus
US9821051B1 (en) 2010-10-28 2017-11-21 Seqirus UK Limited Reducing hospitalization in elderly influenza vaccine recipients
EP2667891B1 (en) 2011-01-27 2021-10-06 Gamma Vaccines Pty Limited Combination vaccines
CN113876945A (zh) 2011-10-06 2022-01-04 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
WO2013088367A1 (en) 2011-12-12 2013-06-20 Novartis Ag Assay for influenza virus hemagglutinins
JP2015505309A (ja) 2011-12-29 2015-02-19 ノバルティス アーゲー 髄膜炎菌ｈ因子結合タンパク質のアジュバントされた組み合わせ
CA2868120C (en) 2012-03-23 2019-02-19 Pitney Pharmaceuticals Pty Limited Kinase inhibitors for the treatment of cancer
EP3530283A1 (en) 2012-06-05 2019-08-28 The Australian National University Vaccination with interleukin-4 antagonists
US9982240B2 (en) 2012-08-03 2018-05-29 Sanofi Pasteur Production of infectious influenza viruses
EP2880014B1 (en) 2012-08-06 2017-05-17 Pitney Pharmaceuticals Pty Limited Compounds for the treatment of mtor pathway related diseases
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
WO2014094041A1 (en) 2012-12-17 2014-06-26 Pitney Pharmaceuticals Pty Limited Treatment of diseases involving mucin
US10357538B2 (en) 2012-12-24 2019-07-23 Northern Sydney Local Health District Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
RU2523614C1 (ru) * 2013-04-09 2014-07-20 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Вакцина против гриппа и способ ее получения
US10364277B2 (en) 2013-07-01 2019-07-30 Newsouth Innovations Pty Limited Diagnosis and treatment of autoimmune diseases
US10286062B2 (en) * 2013-07-09 2019-05-14 Texas Tech University System Universal influenza vaccine
KR20160036669A (ko) * 2013-07-31 2016-04-04 주식회사 쿠라레 투명성, 열 균열 현상 억제가 우수한 폴리비닐 아세탈 필름
US10238739B2 (en) 2014-12-02 2019-03-26 Novartis Ag Manufacture of surfactant-containing compositions with enhanced stability
MY191539A (en) 2015-03-26 2022-06-30 Gpn Vaccines Pty Ltd Streptococcal vaccine
US11013795B2 (en) 2015-06-26 2021-05-25 Seqirus UK Limited Antigenically matched influenza vaccines
KR102790570B1 (ko) 2015-07-07 2025-04-04 세퀴러스 유케이 리미티드 인플루엔자 효능 검정
CN105251002B (zh) * 2015-11-13 2019-02-15 中国人民解放军第三军医大学 一种水包油型纳米乳佐剂及其mrsa纳米乳佐剂疫苗和制备方法
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
KR20260047644A (ko) 2017-03-30 2026-04-08 더 유니버서티 어브 퀸슬랜드 키메라 분자 및 그의 용도
CN111356700A (zh) 2017-09-08 2020-06-30 马弗里克治疗公司 受约束的条件性活化的结合蛋白
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
FI20215508A1 (en) 2020-04-09 2021-10-10 Niemelae Erik Johan Mimetic nanoparticles to prevent the spread of new coronaviruses and reduce the rate of infection
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
AU2021302954A1 (en) 2020-06-30 2023-02-16 Seqirus UK Limited Cold filtration of oil-in-water emulsion adjuvants
CN111803625B (zh) * 2020-09-09 2020-12-18 天津中逸安健生物科技有限公司 一种亚单位流感疫苗裂解剂及其应用
WO2025019631A1 (en) 2023-07-19 2025-01-23 Icahn School Of Medicine At Mount Sinai Immunogenic compositions containing inactivated influenza a virus and cpg oligonucleotide adjuvant and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD155875A1 (de) 1980-12-31 1982-07-14 Willy Nordheim Verfahren zur herstellung eines ballaststoffarmen inaktivierten influenzaimpfstoffes
DD211444A3 (de) 1982-08-19 1984-07-11 Saechsisches Serumwerk Verfahren zur herstellung von influenza-impfstoffen
GB8300467D0 (en) 1983-01-08 1983-02-09 Wellcome Found Equine influenza
DD300833A7 (de) 1985-10-28 1992-08-13 Saechsische Landesgewerbefoerd Verfahren zur herstellung von inaktivierten influenza-vollvirusimpfstoffen
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5376369A (en) * 1987-11-03 1994-12-27 Syntex (U.S.A.) Inc. Vaccine adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB8821049D0 (en) * 1988-09-08 1988-10-05 Health Lab Service Board Method & composition for treatment & prevention of viral infections
US5149531A (en) * 1990-06-27 1992-09-22 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of using cold-adapted live influenza virus vaccine as an antiviral agent against influenza
US5589174A (en) * 1992-09-17 1996-12-31 Takara Shuzo Co., Ltd. Anti-human influenza virus antibody
CA2156525A1 (en) * 1993-02-19 1994-09-01 Susan Dillon Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
CN1124013A (zh) * 1993-02-19 1996-06-05 史密丝克莱恩比彻姆公司 含3-邻位-脱酰基的单磷酰基脂质a的流感疫苗组合物
US5776468A (en) * 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
US6387378B1 (en) * 1993-09-09 2002-05-14 George P. Shibley Device for storage and mucosal delivery of biological or pharmaceutical materials to animals
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DE69533693T2 (de) * 1994-02-24 2005-12-22 Novavax Inc.(n.d.Ges.d.Staates Delaware) Impfstoffe, die paucilamelläre Lipidvesikel als Adjuvans enthalten
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5916879A (en) * 1996-11-12 1999-06-29 St. Jude Children's Research Hospital DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof
JP4578578B2 (ja) * 1997-01-13 2010-11-10 エモリー、ユニバーシティ インフルエンザ感染の治療用化合物及びそれらの組み合わせ
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
AU1145699A (en) * 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
CA2312900A1 (en) * 1997-12-02 1999-06-10 Powderject Vaccines, Inc. Transdermal delivery of particulate vaccine compositions
CA2324504A1 (en) * 1998-03-20 1999-09-23 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
AT408615B (de) * 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
PL355287A1 (en) * 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Intranasal influenza virus vaccine
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
AR054020A1 (es) * 2005-03-23 2007-05-30 Glaxosmithkline Biolog Sa Nuevo uso
US20090028903A1 (en) * 2005-03-23 2009-01-29 Glaxosmithkline Biologicals, S.A. Novel use
NZ594482A (en) 2005-11-04 2012-11-30 Novartis Vaccines & Diagnostic Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
MX2009000660A (es) * 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
US20080014217A1 (en) * 2006-07-17 2008-01-17 Emmanuel Jules Hanon Influenza vaccine
PT2422810E (pt) * 2006-07-17 2014-12-03 Glaxosmithkline Biolog Sa Vacina da gripe
PE20090146A1 (es) * 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
JP2011506290A (ja) * 2007-12-06 2011-03-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム インフルエンザ組成物

Also Published As

Publication number Publication date
EP1618889B1 (en) 2011-02-23
DE60024112D1 (de) 2005-12-22
CY2011008I2 (el) 2014-04-09
EP1618889A3 (en) 2006-06-14
CA2616210C (en) 2014-05-06
ATE309821T1 (de) 2005-12-15
JP2008001725A (ja) 2008-01-10
WO2001022992A2 (en) 2001-04-05
DE122011100035I1 (de) 2011-12-15
ES2250193T3 (es) 2006-04-16
CA2386014A1 (en) 2001-04-05
DK1216053T3 (da) 2006-03-20
AU774921B2 (en) 2004-07-15
GB9923176D0 (en) 1999-12-01
JP2012021030A (ja) 2012-02-02
HK1048434A1 (en) 2003-04-04
CY1111908T1 (el) 2014-04-09
US7238349B1 (en) 2007-07-03
AU7660200A (en) 2001-04-30
EP1216053B1 (en) 2005-11-16
EP2269637A1 (en) 2011-01-05
EP1618889B8 (en) 2011-04-20
JP2003510291A (ja) 2003-03-18
EP1618889A2 (en) 2006-01-25
JP2014205726A (ja) 2014-10-30
DE60024112T2 (de) 2006-08-24
HK1048434B (en) 2006-07-28
ATE499113T1 (de) 2011-03-15
ES2359982T3 (es) 2011-05-30
CA2386014C (en) 2014-05-13
CY2011008I1 (el) 2014-04-09
BR0014386A (pt) 2002-06-18
EP1216053A2 (en) 2002-06-26
EP3103473A1 (en) 2016-12-14
US20070141078A1 (en) 2007-06-21
DE60045668D1 (de) 2011-04-07
CA2616210A1 (en) 2001-04-05
PT1618889E (pt) 2011-05-10
WO2001022992A3 (en) 2001-05-17

Similar Documents

Publication Publication Date Title
DK1216053T3 (da) Influenzavaccine
DK1358319T3 (da) Levende influenzavaccine og fremgangsmåde til fremstilling heraf
DK1113816T3 (da) Influenzavirus-vaccinesammensætning
ATE426412T1 (de) Adjuvante influenza-vakzine
WO2006113214A3 (en) Vaccine against pandemic strains of influenza viruses
EP1270016A4 (en) VACCINE AGAINST AIDS VIRUS CONTAINING A VECTOR OF SENDAI VIRUS
UA84254C2 (ru) МИНИМАЛЬНАЯ ПЛАЗМИДНАЯ СИСТЕМА ДЛЯ ГЕНЕРИРОВАНИЯ ИНФЕКЦИОННЫХ МИНУС-ЦЕПОЧЕЧНЫХ РНК ВИРУСОВ С КЛОНИРОВАННОЙ ВИРУСНОЙ кДНК, КЛЕТКА-ХОЗЯИН, КОТОРАЯ ВКЛЮЧАЕТ ПЛАЗМИДНУЮ СИСТЕМУ, СПОСОБ ПРОДУЦИРОВАНИЯ ИНФЕКЦИОННОГО МИНУС-ЦЕПОЧЕЧНОГО РНК ВИРУСА И СПОСОБ ПРИВИВКИ СУБЪЕКТА ОТ ИНФЕКЦИИ МИНУС-ЦЕПОЧЕЧНОГО РНК ВИРУСА
JP2009539965A5 (https=)
GB2386072A (en) Novel vaccine
EP1471936A4 (en) HIV VACCINE AND METHOD OF USE
EA200301151A1 (ru) Вакцина против натуральной оспы
MX2024003337A (es) Composiciones inmunogenicas contra la influenza.
WO2003103570A3 (en) Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles
MY153290A (en) Multivalent avian influenza vaccines
WO2008115785A3 (en) Multivalent avian influenza vaccines and methods
MX2024003507A (es) Mutantes del virus de la influenza b y usos de los mismos.
DK1401492T3 (da) LTB4 som vaccineadjuvans
DE60120840D1 (de) Impfstoffe basierend auf Mutanten des Virus der infektiösen Bursal-Krankheit
UA62746C2 (en) Emulsion vaccine associated inactivated against newcastle disease, infectious bronchitis of fowls, and syndrome of decreasing egg production-76
DE60233391D1 (de) Vakzine zum schutz von tieren gegen leishmania